| 1. |
|
|
| 2. |
|
|
| 3. |
- Ye, Q, et al.
(författare)
-
A novel pattern of pp65-positive cytomegalic endothelial cells circulating in peripheral blood from a renal transplant recipient
- 2004
-
Ingår i: Acta Histochemica. - : Elsevier BV. - 0065-1281. ; 106:2, s. 107-110
-
Tidskriftsartikel (refereegranskat)abstract
- The present study reports a novel pattern of cytomegalic endothelial cells (CEC) in peripheral blood from a female renal transplant recipient infected with human cytomegalovirus (HCMV), which has not been reported previously. Localization of specific early antigen of HCMV, pp65 antigen, was examined by immunohistochemistry. Staining of an endothelial cell marker (CD34) was used to characterize endothelial cells. It is demonstrated that many leukocytes surrounded and adhered to a protein-like material, in which pp65-positive CEC were detected. The composition and function of this protein-like material are yet unknown. The patient tacked clinical symptoms of HCMV disease. Furthermore, similar localization patterns were found in other renal. transplant recipients suffering from HCMV infections as determined by real-time PCR to detect HCMV DNA in blood. These patients showed no or only minor clinical symptoms of HCMV infection. It is suggested that these novel Localization patterns of CEC may play a role in the host defense in patients infected with HCMV, but the exact relation between HCMV infection and CEC formation needs further investigation. (C) 2004 Elsevier GmbH. All rights reserved.
|
|
| 4. |
- Ye, Q, et al.
(författare)
-
Prospective study of relationship between cytomegalovirus pneumonia and viral load in renal transplant recipients
- 2004
-
Ingår i: Transplantation Proceedings. - : Elsevier BV. - 0041-1345. ; 36:10, s. 3036-3041
-
Tidskriftsartikel (refereegranskat)abstract
- The present study prospectively examined the relationship between cytomegalovirus interstitial pneumonia (CMV-IP) and viral load among 56 renal transplant recipients. We sought to identify the cutoff of viral load to predict CMV-IP. Blood samples were obtained weekly within the first 2 months and every second week during 2 to 6 months after kidney transplantations. A commercial real-time polymerase chain reaction (PCR)-method was applied to quantify CMV-DNA in plasma or in leukocytes. Among 54 renal transplant recipients who were analyzed for CMV-DNA in the blood (96.4%), 8 experienced CMV-IP (14.3%) and 2 died (3.6%). After kidney transplantation, CMV-DNA loads were near 0 in plasma before the week 4 and before the week 3 in leukocytes among both groups. From week 5 (week 4, in leukocytes), plasma CMV-DNA loads in the CMV-IP group increased, the peak value reached at week 8 in plasma and the week 9 in leukocytes. Whereas, the CMV-DNA loads both in plasma and in leukocytes in the non-CMV-IP group fluctuated at lower levels, those in plasma were significantly different between the 2 groups at the weeks 5, 7, and 9. For CMV-DNA in leukocytes, there were significant differences between 2 groups from week 6 to week 11. The present study demonstrated that dynamic determination of CMV-DNA may predict the occurrence of CMV-IP. Viral loads over 10(4) copies/mL plasma continuing for 3 weeks may serve as a cutoff to predict CMV-IP.
|
|
| 5. |
|
|
| 6. |
- Luo, Guanghua, et al.
(författare)
-
Apolipoprotein M
- 2004
-
Ingår i: Lipids in Health and Disease. - 1476-511X. ; 3
-
Forskningsöversikt (refereegranskat)abstract
- Apolipoprotein M (apoM) is a 26-kDa protein that is mainly associated with high-density lipoprotein (HDL) in human plasma, with a small proportion present in triglyceride-rich lipoproteins (TGRLP) and low-density lipoproteins (LDL). Human apoM gene is located in p21.31 on chromosome 6 (chromosome 17, in mouse). Human apoM cDNA (734 base pairs) encodes 188-amino acid residue-long protein. It belongs to lipocalin protein superfamily. Human tissue expression array study indicates that apoM is only expressed in liver and in kidney and small amounts are found in fetal liver and kidney. In situ apoM mRNA hybridization demonstrates that apoM is exclusively expressed in the hepatocytes and in the tubule epithelial cells in kidney. Expression of apoM could be regulated by platelet activating factor (PAF), transforming growth factors (TGF), insulin-like growth factor (IGF) and leptin in vivo and/or in vitro. It has been demonstrated that apoM expression is dramatically decreased in apoA-I deficient mouse. Hepatocyte nuclear factor-1alpha (HNF-1alpha) is an activator of apoM gene promoter. Deficiency of HNF-1alpha mouse shows lack of apoM expression. Mutations in HNF-1alpha (MODY3) have reduced serum apoM levels. Expression of apoM is significantly decreased in leptin deficient (ob/ob) mouse or leptin receptor deficient (db/db) mouse. ApoM concentration in plasma is positively correlated to leptin level in obese subjects. These may suggest that apoM is related to the initiation and progression of MODY3 and/or obesity.
|
|
| 7. |
- Xu, Hong-Tao, et al.
(författare)
-
Effects of fucosylated milk of goat and mouse on Helicobacter pylori binding to Lewis b antigen
- 2004
-
Ingår i: World Journal of Gastroenterology. - Beijing : WJG Press. - 1007-9327 .- 2219-2840. ; 10:14, s. 2063-2066
-
Tidskriftsartikel (refereegranskat)abstract
- Aim:To evaluate the effects of animal milk containing fucosylated antigens on Helicobacter pylori (H pylon) binding to Lewis b antigen. Methods:A mammary gland expression vector containing human α1-3/4-fucosyltransferase cDNA sequences was constructed. Transient expression of human(α1-3/4-fucosyltransferase cDNA in goat mammary cell and establishment of transgenic mice were performed. The adhesion inhibitory properties of milk samples were analyzed by using Hpylori. Results: Goat milk samples were found to inhibit bacterial binding to Lewis b antigen. The highest inhibition was observed 42 h after injection of the plasmid. The binding activity of Hpylori to Lewis b antigen reduced mostly, by 83%, however milk samples from transgenic mice did not inhibit Hpylori binding to Lewis b antigen. Conclusion: The use of “humanized“ animal milk produced by the transgenic introduction of fucosylated antigen can perhaps provide an alternative therapy and preventive measure for Hpylori infection.
|
|
| 8. |
- Xu, Ning, et al.
(författare)
-
ACTH decreases the expression and secretion of apolipoprotein B in HepG2 cell cultures
- 2001
-
Ingår i: Journal of Biological Chemistry. - 1083-351X. ; 276:42, s. 38680-38684
-
Tidskriftsartikel (refereegranskat)abstract
- Administration of adrenocorticotropic hormone (ACTH) has been shown to decrease plasma concentrations of apolipoprotein B (apoB) containing lipoproteins, including lipoprotein(a), in man. However, the mechanism behind this hypolipidemic effect is unknown. This study aimed at distinguishing between the main possibilities (increased elimination or decreased production of lipoproteins) using HepG2 cell cultures. Addition of ACTH to the cell culture medium selectively down-regulated apoB mRNA expression and apoB secretion in a dose-dependent manner. At 100 pmol/liter ACTH, the apoB mRNA level was about 40% lower than in the untreated cells, and the secretion of apoB into the medium was decreased to a similar extent. The expression and secretion of other apolipoproteins (apoA-I, apoE, and apoM), however, were not affected by ACTH. Under normal culture conditions the level of secretion of apoB from HepG2 cells is quite low. In the presence of 0.4 mmol/liter oleic acid secretion of apoB increased 3-fold, but this phenomenon was not seen in ACTH-treated cells. Binding and internalization of radiolabeled low density lipoprotein (LDL) by HepG2 cell, as well as LDL-receptor mRNA and scavenger receptor B-I mRNA levels, were not influenced by ACTH. In conclusion, ACTH directly and selectively down-regulated the production and secretion of apoB in HepG2 cell cultures, suggesting that a principal mechanism behind the cholesterol-lowering effect of ACTH in vivo may be a decreased production rate of apoB-containing lipoproteins from the liver.
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
- Xu, Ning, et al.
(författare)
-
Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells.
- 2002
-
Ingår i: Biochemical and Biophysical Research Communications. - : Elsevier BV. - 1090-2104 .- 0006-291X. ; 292:4, s. 944-950
-
Tidskriftsartikel (refereegranskat)abstract
- Apolipoprotein M (apoM) is a recently discovered human apolipoprotein predominantly present in high-density lipoprotein (HDL) in plasma, exclusively expressed in liver and in kidney. The function of apoM is yet unknown. The human apoM gene is located in the major histocompatibility complex class III region on chromosome 6. Because many genes located in this region are related to the immune response, we have investigated whether apoM might also be involved in the host inflammatory response. In this study we examined effects of the platelet-activating factor (PAF), tumor necrosis factor (TNF-alpha), and interleukin-1alpha (IL-1alpha) on apoM expression in a hepatoblastoma cell line, HepG2 cells. PAF significantly enhanced the apoM mRNA levels and the secretion of apoM in HepG2 cell cultures. The enhancement of apoM secretion is seen at a low concentration of PAF (2 ng/ml), whereas a high concentration of PAF increases both the apoM mRNA levels and apoM secretion. Neither TNF-alpha nor IL-1alpha influenced apoM mRNA level and secretion. Furthermore, Lexipafant, a PAF-receptor (PAF-R) antagonist significantly suppressed the mRNA level and the secretion of apoM in HepG2 cells in a dose-dependent manner. Neither PAF nor Lexipafant influenced the mRNA levels and the secretion of apoA-I, apoB and apoE in HepG2 cells, indicating that the effects of PAF or Lexipafant on the apoM production on hepatic cells are selective for apoM. The cellular mechanism of the effects of PAF or Lexipafant on apoM metabolism requires further investigations.
|
|
| 13. |
- Xu, Ning
(författare)
-
Interaction of Triglyceride-rich Lipoproteins with Platelets and Vitamin K-dependent Coagulation Factors
- 2000
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- 1. During incubation of platelets with 3H-arachidonic acid (20:4, n-6) and 14C-cholesterol doubly labelled and colloidal gold labelled chylomicrons (CMs) and chylomicron remnants (CMRs) CMs were taken up more efficiently than CMRs. Addition of unlabelled CMs, VLDLs, LDLs and HDLs decreased the uptake of labelled CMs. Electron microscopic studies demonstrated an accumulation of CM-Au's both in the open canalicular system and cytoplasm of the platelets. There was no evidence for a lipoprotein receptor mediated breakdown of CMRs. 2. Plasma exposed CMs and CM-prothrombin complexes could induce platelet aggregation and enhance the platelet serotonin- and arachidonic acid release. Platelet aggregation induced by plasma exposed CMs could be inhibited in a dose dependent manner by an antiserum against prothrombin. Coagulation factor Xa inhibitor (TenStop) inhibited platelet aggregation and serotonin release that were induced by CM-prothrombin complexes in a dose-dependent manner. Native chyle CMs did not induce platelet aggregation, but decreased ADP and thrombin induced platelet aggregation and serotonin release. Neither did CMRs induce platelet aggregation, but they potentiated the aggregation and serotonin release induced by ADP and thrombin. 3. The ability of chyle CMs to bind human prothrombin was studied in vitro. The binding was Ca2+ and temperature dependent but could not be reversed with EDTA. The metabolism in vivo of CM-125I-prothrombin complexes was compared to that of free 125I-prothrombin injected in saline or together with CMs. The plasma decrease of 125I-prothrombin was faster in the group obtained CM-125I-prothrombin complexes than in the other groups. The radioactivity in the liver was higher in the group that obtained CM-125I-prothrombin complexes. 4. All vitamin K-dependent coagulation proteins (factors VII, IX, and X, prothrombin, proteins C and S) and C4b binding protein (C4BP) were found in TG-rich lipoproteins of human plasma. A relative increase of prothrombin, protein S and C4BP was seen in TG-rich lipoproteins after a fat meal compared to the fasting lipoproteins. There was no association of the coagulation proteins with LDLs and HDLs. Nor were coagulation factor V, serum amyloid P component or thrombomodulin associated with TG-rich lipoproteins in vivo.
|
|
| 14. |
- Xu, Ning, et al.
(författare)
-
Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells.
- 2004
-
Ingår i: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids. - : Elsevier BV. - 1388-1981. ; 1683:1-3, s. 33-37
-
Tidskriftsartikel (refereegranskat)abstract
- Apolipoprotein M (apoM) is a novel apolipoprotein presented mostly in high-density lipoprotein (HDL) in human plasma, and is exclusively expressed in liver and in kidney. The pathophysiological function of apoM has not yet been elucidated. Apolipoprotein B (apoB), the characteristic apolipoprotein of low-density lipoprotein (LDL), is like apoM, a very hydrophobic protein, and thereafter they both must co-circulate with lipoprotein particles in plasma. The cytokine, transforming growth factor-beta (TGF-beta), has been shown to decreased apoB secretion in HepG2 cells, and we hypothesized that TGF-beta may have the same effects on apoM expression in HepG2 cells. In the present study, we used real-time RT-PCR to analyze apoM and apoB mRNA levels during administration of TGF-beta, as well as TGF-alpha, epidermal growth factor (EGF) and hepatic growth factor (HGF). TGF-beta significantly inhibited both apoM and apoB mRNA expression in HepG2 cells. The inhibitory effects of TGF-beta were dose-dependent, i.e. 1 ng/ml of TGF-beta decreased apoM mRNA levels by 30%, and 10 or 100 ng/ ml of TGF-beta decreased apoM mRNA levels more than 65%. The effect of TGF-beta on apoB mRNA expression was slightly weaker than that of apoM, with a maximum effect at 10 or 100 ng/ml TGF-beta where apoB mRNA levels decreased about 55%. The inhibitory effects of TGF-beta on apoM and apoB mRNA levels also increased with increasing incubation time, where the maximum effect was obtained at 24 h. Moreover TGF-alpha, EGF and HGF all decreased both apoM and apoB mRNA levels, but to a less extent than TGF-beta. Further, all four cytokines had more pronounced effects on apoM mRNA expression than apoB mRNA expression. The present study suggested that apoM, like apoB, may be involved in the hepatic lipoprotein assembly in vivo. (C) 2004 Elsevier B.V. All rights reserved.
|
|
| 15. |
- Zhang, XY, et al.
(författare)
-
Expression pattern of apolipoprotein M during mouse and human embryogenesis
- 2004
-
Ingår i: Acta Histochemica. - : Elsevier BV. - 0065-1281. ; 106:2, s. 123-128
-
Tidskriftsartikel (refereegranskat)abstract
- Apolipoprotein M (apoM) is a recently discovered human apolipoprotein predominantly present in high-density lipoprotein (HDL), and in minor proportions in triglyceride-rich lipoprotein (TGRLP) and low-density lipoprotein (LDL). The gene encoding apoM is present in all mammalian genomes. The identity of the apoM gene of human, rat and mouse is over 80%. However, the (patho)physiological functions of apoM are unknown yet. In the present study, we investigated apoM expression patterns during mouse and human embryogenesis. ApoM transcripts were detectable in mouse embryos from day 7.5 to day 18.5. ApoM was expressed at low levels at day 7.5, its expression increased significantly at day 9.7, decreased at day 10.5, and then increased continually up to day 18.5. ApoM-positive cells appeared mainly in liver of day-12 embryos as detected by in situ hybridization. In day-15 embryos, apoM was expressed in both liver and kidney. During human embryogenesis, apoM was mainly expressed in liver and kidney and little was found in small intestine as determined by mRNA array of human fetal. normal tissues. ApoM was also detected in stomach and skeletal muscle in early stages of embryogenesis (3-5 months). (C) 2004 Elsevier GmbH. All rights reserved.
|
|
| 16. |
- Zhang, XY, et al.
(författare)
-
Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization
- 2003
-
Ingår i: Acta Histochemica. - : Elsevier BV. - 0065-1281. ; 105:1, s. 67-72
-
Tidskriftsartikel (refereegranskat)abstract
- Apolipoprotein M (apoM) is a recently discovered human apolipoprotein predominantly present in high-density lipoprotein (HDL), and in minor proportion in triglyceride-rich lipoprotein (TGRLP) and low-density lipoprotein (LDL). The gene coding for apoM has been detected in all mammal genomes. The function of apoM is unknown yet. In the present study, we demonstrated that apoM is exclusively expressed in a strong manner in adult liver and kidney, and is expressed weakly in fetal liver and kidney as detected with human multiple tissue expression array. Both immumohistochemical staining and apoM mRNA in situ hybridization demonstrated that apoM was exclusively expressed in hepatocytes in human liver and in tubular epithelial cells in human kidney. The present study helps to elucidate the pathophysiological functions of apoM in vivo.
|
|
| 17. |
|
|
